IgA multiple myeloma is a subtype of myeloma in which the cancerous plasma cells produce immunoglobulin A, accounting for roughly 20 to 25 percent of all myeloma cases. It shares the core features of myeloma in general, including bone destruction, anemia, and kidney damage, but it carries some distinct clinical quirks that affect how it is diagnosed, monitored, and even how it behaves at relapse. Compared to the more common IgG subtype, IgA myeloma tends to have a somewhat worse prognosis and presents a few diagnostic headaches that both patients and clinicians should understand.
What Makes IgA Myeloma Different
All forms of myeloma involve a single clone of plasma cells multiplying out of control in the bone marrow and churning out one specific type of antibody, called a monoclonal protein or M-protein. In IgA myeloma, that protein is immunoglobulin A. IgA molecules have an unusual tendency to form dimers and higher-order polymers, meaning two or more IgA units link together into larger complexes. Structural studies of IgA myeloma proteins have shown that the monoclonal IgA circulates predominantly as a disulfide-bonded dimer, with smaller amounts of monomers and larger oligomeric forms also present.1PubMed Central. Structural characterization of a human monoclonal IgA protein This polymerization matters clinically: larger protein complexes thicken the blood more than single antibody molecules do, which is why IgA myeloma carries a higher risk of certain complications like hyperviscosity syndrome.
IgA myeloma also appears to cluster with certain high-risk genetic abnormalities more often than other subtypes. Molecular classification work by the International Myeloma Working Group has linked certain chromosomal translocations, including t(4;14) and t(14;16), to IgA heavy chains.2Leukemia. International Myeloma Working Group (IMWG) Molecular Classification of Multiple Myeloma More recent data have found that IgA myeloma is associated with a higher prevalence of adverse cytogenetic features like 1q gain and del(17p).3Clinical Lymphoma Myeloma and Leukemia. Abstracts: Proceedings of the Society of Hematologic Oncology 2026 Annual Meeting Multiple Myeloma These genetic features are associated with more aggressive disease behavior and resistance to some therapies, which partly explains why IgA myeloma tends to carry a worse outlook.
Symptoms You Might Experience
The symptoms of IgA myeloma overlap heavily with myeloma in general. Most people are diagnosed because of bone pain (especially in the back or ribs), unexplained anemia that causes fatigue, elevated calcium levels, or kidney problems discovered on routine blood work. These are sometimes grouped under the acronym CRAB: calcium elevation, renal insufficiency, anemia, and bone lesions. None of these symptoms are unique to the IgA subtype, and many patients initially assume their back pain or tiredness has a more mundane explanation.
Where IgA myeloma diverges is in complications driven by the physical properties of the IgA molecule itself. Because IgA tends to polymerize into larger complexes, the blood can become abnormally thick, a condition called hyperviscosity syndrome. While hyperviscosity is a well-known complication of Waldenström macroglobulinemia (an IgM-producing cancer), it is rare in myeloma overall. When it does occur in myeloma, IgA subtypes are disproportionately represented. Symptoms of hyperviscosity include blurred or worsening vision, headaches, nosebleeds, confusion, and sometimes mucosal bleeding. In one reported case, an IgA lambda myeloma patient developed significant bilateral eye findings including venous congestion and flame hemorrhages, with serum viscosity measured at over ten centipoise, well above normal.4QJM: An International Journal of Medicine. Hyperviscosity syndrome in IgA multiple myeloma When hyperviscosity is identified, emergency treatment with plasmapheresis can rapidly reduce the protein load and relieve symptoms.5PubMed Central. Viscous Vengeance: A Case Report of Hyperviscosity Syndrome in IgA Lambda Multiple Myeloma
Kidney Damage in IgA Myeloma
Kidney disease is one of the most common serious complications of myeloma of any subtype. It increases both how sick patients become and how long they survive.6PubMed. Kidney disease in multiple myeloma The most frequent kidney lesion in myeloma is light chain cast nephropathy, which happens when excess free light chains (the smaller partner of the antibody molecule) clog up the kidney’s filtration tubes. This form of kidney injury typically shows up as sudden, severe kidney failure alongside very high levels of free light chains in the blood.6PubMed. Kidney disease in multiple myeloma Other mechanisms include hypercalcemia (excess calcium damaging kidney tissue) and infection-related injury.7PubMed Central. Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management
IgA myeloma can also cause a more specific form of kidney damage. Studies of kidney biopsies in patients with monotypic IgA deposits have identified distinct patterns of glomerular disease, including a condition called IgA-proliferative glomerulonephritis with monoclonal immunoglobulin deposits. In many of these cases, even when overt myeloma was not yet present, careful bone marrow studies revealed a subtle underlying plasma cell proliferation. Treatment with anti-myeloma drugs appeared to improve kidney outcomes in these patients, underscoring the importance of hematological follow-up when IgA-related kidney disease is found.8PubMed. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits
Why IgA Myeloma Is Harder to Diagnose and Track
Diagnosing myeloma of any type generally starts with blood tests looking for an abnormal monoclonal protein. The standard initial workup includes serum protein electrophoresis (SPEP), which separates blood proteins by electrical charge and reveals an abnormal spike if a monoclonal protein is present, along with immunofixation to identify the specific antibody type and serum free light chain measurements.9PubMed. A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing
Here is where IgA myeloma creates problems. IgA proteins frequently migrate in the beta region of the electrophoresis strip rather than the gamma region where most antibodies land. This means the monoclonal spike can be masked by other normal beta-migrating proteins like transferrin and complement, making it difficult or impossible to accurately measure. In one study of IgA myeloma patients, SPEP bands were only quantifiable in about two-thirds of samples, and roughly eight percent of patients presented with what appeared to be oligosecretory disease, where the M-protein measured below the threshold that would normally be trackable.10PubMed. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma For clinicians, this means standard SPEP alone can underestimate how much tumor protein is actually circulating, which in turn makes it harder to judge how well treatment is working.
IgA myeloma can also produce misleading laboratory values. Paraproteins at high concentrations can interfere with routine chemistry tests, creating artifacts like pseudohyponatremia (falsely low sodium readings) and pseudohyperphosphatemia (falsely high phosphorus). These spurious results can lead to unnecessary workups or inappropriate treatments if the lab artifacts are not recognized for what they are.11Journal of Human Health Research. Iga Myeloma with Increased Anion Gap, Pseudo hyperphosphatemia and Pseudohyponatremia
Monitoring Treatment Response
Because SPEP is unreliable for many IgA myeloma patients, alternative assays have become increasingly important. The Hevylite assay, which measures intact IgA kappa and IgA lambda separately, offers a more sensitive way to track the involved and uninvolved immunoglobulin pair. In a comparison study, the Hevylite (heavy/light chain) ratio normalized earlier than traditional markers in the majority of IgA patients evaluated. In eight of eleven patients studied, the ratio returned to normal while both immunofixation and flow cytometry still showed residual disease. In every case, normalization of the ratio preceded normalization of the other markers at the next evaluation timepoint.12Blood. Comparison Of Hevylite™ Assay and Plasma Cell Immunophenotyping For Response Evaluation and Residual Disease Characterisation In IgA Myeloma
This is a double-edged finding. On one hand, the Hevylite ratio can offer earlier reassurance that treatment is heading in the right direction. On the other hand, a normal ratio does not necessarily mean the disease is gone; residual tumor may still be detectable by more sensitive methods. For IgA myeloma specifically, clinicians often need to combine multiple monitoring tools rather than relying on any single test.
From MGUS to Myeloma
Most myeloma cases are preceded by a precursor condition called monoclonal gammopathy of undetermined significance, or MGUS, in which a small monoclonal protein is present but no organ damage has occurred. Not all MGUS progresses to cancer; the risk depends on several factors, including the size of the M-protein and which immunoglobulin type is involved.
Recent data show that progression risk clusters into two distinct groups. IgA MGUS with an M-protein of 1.0 g/dL or greater carries a notably higher progression rate compared to IgA MGUS below that threshold. The higher-risk group had a progression rate of about 7.75 per thousand person-years, similar to the rate seen in IgG MGUS at 1.5 g/dL or above. Below these thresholds, the risk dropped substantially to around 2 per thousand person-years for IgA.13Blood Neoplasia. IgA or IgM MGUS less than 1.0 g/dL is at low risk of progression to neoplasm So for someone with IgA MGUS, the size of the M-protein matters a great deal in determining how closely they need to be watched.
Separately, research into immune markers in MGUS patients has shown that changes in the immune profile can signal impending progression to myeloma years before clinical diagnosis. In one study, over half of MGUS patients who eventually progressed to myeloma had a high-risk immune marker score, and this score was detectable up to five years before the myeloma diagnosis itself. Among those who did not progress, virtually none had a high-risk score.14JAMA Oncology. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma This kind of early-warning tool could eventually help clinicians decide which MGUS patients need more aggressive surveillance.
Treatment Approaches
Treatment for IgA myeloma follows the same general framework as other myeloma subtypes. For younger, fit patients, the goal is typically induction chemotherapy followed by autologous stem cell transplant, then maintenance therapy. For older patients or those with significant health issues, chemotherapy combinations without transplant are the standard approach.
Modern induction regimens have pushed response rates higher across all subtypes. A recent phase 3 trial in older fit patients compared three approaches: a traditional regimen of bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone; a newer combination of carfilzomib, lenalidomide, and dexamethasone (KRd); and the same KRd regimen with the addition of daratumumab (D-KRd). The rates of undetectable measurable residual disease, a deep response marker, were dramatically higher in the newer arms. Roughly 54 percent of patients on KRd and 61 percent on D-KRd achieved this depth of response, compared to 27 percent on the older regimen.15PubMed. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT) While these results apply to myeloma broadly, the availability of regimens that achieve deeper responses is particularly relevant for IgA patients given their higher-risk genetic profile.
Despite advances, the IgA subtype consistently shows somewhat inferior long-term survival compared to IgG myeloma. One large analysis found that IgA myeloma had the lowest five-year overall survival at about 69 percent, compared to roughly 77 percent for IgG myeloma. At eight years, the gap persisted, with IgA patients showing about 69 percent survival versus 73 percent for non-IgA patients.16Transplantation and Cellular Therapy. IgA Multiple Myeloma: Symptoms, Diagnosis & Treatment After autologous stem cell transplant specifically, progression-free survival was similar between IgG/IgA and light chain myeloma groups, though patients with IgG/IgA myeloma had a somewhat lower complete response rate of 28 percent compared to 38 percent in light chain myeloma.17Blood. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
Newer Therapies at Relapse
When myeloma returns after initial treatment, the landscape of options has expanded considerably in recent years. Bispecific antibodies and CAR-T cell therapy targeting BCMA (a protein found on myeloma cells) represent two of the most promising advances. In a study of patients bridged to CAR-T therapy using different regimens, bispecific antibodies proved the most effective bridging option, achieving a 100 percent overall response rate compared to roughly 46 to 53 percent for other approaches like anti-CD38 antibodies or chemotherapy.18Blood Cancer Discovery. Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma These therapies are not specific to IgA myeloma, but they are particularly relevant because IgA patients are more likely to harbor the adverse genetics that predict earlier relapse and resistance to conventional drugs.
Extramedullary Relapse
One distinctive feature of IgA myeloma at relapse is its tendency to show up outside the bone marrow, in locations where myeloma does not normally live. This is called extramedullary disease. Case reports have documented IgA myeloma relapsing as plasmacytomas in unusual sites: the pleura surrounding the lungs, with no bone marrow involvement at all, just a year after transplant19PubMed Central. Extramedullary relapse of Immunoglobulin A-kappa myeloma manifesting as plasmacytoma of the pleura without bone marrow involvement and following autologous bone marrow transplant; as multiple intracranial masses despite recent bortezomib therapy20PubMed Central. Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy; and even as a testicular mass three years into remission.21PubMed Central. Relapsed IgA Multiple Myeloma as Testicular Plasmacytoma after Quadrable Novel Therapy and Autologous Stem Cell Transplant
Extramedullary relapse is clinically important for several reasons. Because the tumor is outside the marrow, standard blood tests and bone marrow biopsies can come back clean even while the disease is actively growing. Patients and clinicians need to maintain a high index of suspicion for new lumps, neurological symptoms, or unexplained pain in unusual locations, especially in the first few years after transplant. Imaging with PET-CT is often critical for identifying these deposits.
Infection Risk and Immune Deficiency
Infection is the leading cause of illness and death in myeloma patients across all subtypes, driven by the combined immune suppression from the disease itself, the treatments used, and individual patient factors.22The Lancet Haematology. Infections in multiple myeloma: a consensus statement of the International Myeloma Society Myeloma inherently weakens the immune system by crowding out normal plasma cells, which means patients produce less of the functional antibodies they need to fight off bacteria and viruses. Treatment with drugs like proteasome inhibitors, immunomodulatory agents, and steroids further compounds this vulnerability.
Preventive strategies are considered essential but remain somewhat inconsistent across treatment centers. The International Myeloma Society has outlined that optimal prevention includes vaccination against common pathogens, antimicrobial prophylaxis during vulnerable treatment windows, and immunoglobulin replacement for a subset of patients with very low antibody levels.22The Lancet Haematology. Infections in multiple myeloma: a consensus statement of the International Myeloma Society Prophylactic antibiotics serve dual purposes, targeting both infection and the inflammatory environment that can support tumor growth.23PubMed Central. Multiple Myeloma: What Do We Do About Immunodeficiency? Despite this, there are no universally accepted guidelines for infection prevention in myeloma, meaning the specifics of prophylaxis can vary considerably depending on your treatment team.
Quality of Life During Treatment
Living with myeloma treatment affects daily life in ways that go beyond tumor markers and lab results. Research on patients receiving non-transplant regimens has shown that several quality-of-life domains improve within the first months of treatment: physical functioning, emotional functioning, and overall health status all trended upward, as did patients’ sense of future perspective and reduction in disease-related symptoms. At the same time, side effects from therapy and changes in body image worsened, and breathlessness increased significantly. The pattern highlights a common tension in myeloma care: the disease itself may improve while the treatment introduces its own burdens.
For IgA myeloma patients specifically, the diagnostic challenges described earlier can add a layer of anxiety. When standard blood tests cannot reliably measure your M-protein, it can be harder to get clear-cut reassurance that treatment is working. Understanding the limitations of SPEP in IgA disease and knowing that alternative assays exist can help patients advocate for appropriate monitoring and reduce some of the uncertainty that comes with ambiguous test results.